Biotechnology Get all the latest news from the field of biotechnology and its many applications, including testing, treatment, and pharmaceuticals. This category includes research, clinical, and study results, as well as stories about the newest breakthroughs in the industry. Read stories about upcoming conferences and symposiums, along with releases regarding patents, legal activity, company performance, and market analysis.

Latest

Dec 05, 2016, 03:00 ET AOP Orphan and PharmaEssentia Announce Pivotal Phase III Results for Ropeginterferon Alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2016

- At 12 months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete Hematologic Response...


Dec 05, 2016, 01:00 ET BrainStorm Announces NurOwn® Data to be Highlighted at the 27th International Symposium on ALS/MND

BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today data...


Dec 04, 2016, 19:30 ET Blueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically...


Dec 04, 2016, 19:30 ET Favorable Response Rates Suggest Promise of Ibrutinib (IMBRUVICA®) Combination Therapy in Two Common Types of Non-Hodgkin's Lymphoma

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced encouraging efficacy and safety findings from two separate studies...


Dec 04, 2016, 13:01 ET Neue Daten zu Zebinix® (Eslicarbazepinacetat) 1 x täglich als Zusatztherapie zeigen gute Anfallskontrolle und Verträglichkeit bei Patienten mit Anfällen fokalen Ursprungs

NUR FÜR MEDIEN IN EMEA-LÄNDERN - NICHT FÜR MEDIEN IN SCHWEIZ/ÖSTERREICH/USA Zebinix® (Eslicarbazepinacetat) als Zusatztherapie bei Patienten...


Dec 04, 2016, 13:01 ET Nuevos datos de Zebinix® (acetato de eslicarbazepina), administrado una vez al día como terapia adyuvante, muestran buen control de las crisis y tolerabilidad en personas con crisis (focales) de inicio parcial

SOLO PARA LOS MEDIOS DE LA REGIÓN EMEA; NO PARA LOS MEDIOS SUIZOS/AUSTRIACOS/ESTADOUNIDENSES Zebinix® (acetato de eslicarbazepina) ofrece una...


Dec 04, 2016, 12:00 ET SystemOne and Daktari Announce Partnership to Bring Connected Diagnostics to Developing World

SystemOne, a company focused on connecting diagnostics and providing connected diagnostics software platforms for the developing world, and Daktari...


Dec 03, 2016, 20:30 ET CSL Behring Presents New Phase III Analysis of IDELVION® for Hemophilia B at the 2016 American Society of Hematology Annual Meeting

Global biotherapeutics leader CSL Behring today announced new results from its Phase III clinical development program evaluating IDELVION®...


Dec 03, 2016, 19:00 ET IMBRUVICA® (ibrutinib) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5-Year Analysis and Long-Term RESONATE-2 Follow-up Data at ASH 2016 Show Lasting Efficacy

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced long-term follow-up results evaluating up to five years of IMBRUVICA®...


Dec 03, 2016, 13:52 ET Amorce des investissements biopharmaceutiques mondiaux lors de l'événement Biotech Showcase™ 2017 du mois de janvier

La ville de San Francisco sera le point d'accueil central de l'innovation et de l'investissement biopharmaceutiques du 9 au 11 janvier 2017,...


Dec 03, 2016, 13:49 ET Biopharma-Investoren der Welt beginnen das Jahr im Januar auf dem Biotech Showcase™ 2017

San Francisco wird anlässlich des Biotech Showcase™, der führenden Veranstaltung für Biotech-Investoren des Jahres, die vom 9.–11. Januar...


Dec 03, 2016, 13:13 ET Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study

Results from the Phase II SUSTAIN study show that SEG101 (crizanlizumab, formerly SelG1), an anti-P-selectin antibody, reduced the median annual...


Dec 03, 2016, 13:00 ET Sickle Cell Disease Research Shows Progress in Preventing Related Complications and Death

Sickle cell disease (SCD) is an inherited chronic disorder characterized by rigid, sickle-shaped red blood cells that get stuck in veins and block...


Dec 03, 2016, 13:00 ET Pairnomix Presents Systematic Approach To Identifying Approved Drugs That May Be Repurposed For Treatment Of Rare Genetic Diseases

Pairnomix, LLC, a genetic research company and member of the Patient-Empowered Precision Medicine Alliance (PEPMA) recognized by the White House,...


Dec 03, 2016, 11:00 ET Bioengineering Innovations Show Promise for Improving Treatments and Drug Delivery

In five studies being presented today during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, researchers...


Dec 02, 2016, 17:21 ET Shire Reports on Four Decades of Real-World Safety Experience With FEIBA® [Anti-Inhibitor Coagulant Complex]

Shire plc (LSE: SHP; NASDAQ: SHPG), the leading biotechnology company focused on serving individuals with rare diseases, is presenting an update...


Dec 02, 2016, 16:00 ET Amgen Announces Launch Of Blood Counts™ And Collaboration With StoryCorps To Record And Share Stories Of Those Impacted By Multiple Myeloma

Amgen (NASDAQ:AMGN) today announced the launch of Blood Counts™, a national campaign dedicated to raising awareness of multiple myeloma and the...


Dec 02, 2016, 14:52 ET DNA Diagnostics Center® Announces Acquisition of IDENTIGENE®, LLC

DNA Diagnostics Center® (DDC® or the Company), one of the world's largest private DNA testing companies, announces the acquisition of IDENTIGENE®...


Dec 02, 2016, 14:00 ET New England Biolabs® Passion in Science Awards® Recipients Are Redefining What it Means to Be a Scientist in Today's World

From providing clean drinking water in developing countries to creating beautiful works of art with living neurons, scientists at the recent...


Dec 02, 2016, 13:20 ET Global biopharma investment kicks off at Biotech Showcase™ 2017 in January

San Francisco will be the center of biopharma innovation and investment January 9–11, 2017 at Biotech Showcase™, the leading biotech investor event...


Dec 02, 2016, 13:04 ET Groundbreaking MMRF CoMMpass Study(SM) Affirmed as Premier Genomics Data Set in Multiple Myeloma

The Multiple Myeloma Research Foundation (MMRF) today announced that 19 research presentations from the MMRF CoMMpass StudySM—the largest and most...


Dec 02, 2016, 12:30 ET 11th Double Helix Medals raises $4.3 million for biomedical research and education at Cold Spring Harbor Laboratory

More than $4.3 million was raised last night at Cold Spring Harbor Laboratory's (CSHL) 11th Double Helix Medals dinner (DHMD). The gala was held at...


Dec 02, 2016, 11:30 ET In Vitro Diagnostics/IVD Market Worth 78.74 Billion USD by 2021

According to a new market research report "In Vitro Diagnostics/IVD Market by Product (Instruments, Reagents, Software), Technology (Immunoassay,...


Dec 02, 2016, 11:10 ET Global Nanobiotechnology Report 2015-2025 - Focus on Applications, Markets and Companies with Profiles of 250+ Companies - Research and Markets

Research and Markets has announced the addition of Jain PharmaBiotech's new report "Nanobiotechnology Applications, Markets and Companies" to...